CSPC Pharmaceutical Group Limited, an investment holding company, engages in the research and development, manufacture, and sale of pharmaceutical products in the People's Republic of China, other Asian regions, the Americas, Europe, and internationally. It operates through Finished Drugs, Bulk Products, and Functional Food and Others segments. The company provides NBP soft capsules and injections for acute ischemic stroke and memory and mental impairment; Oulaining capsules and injections to treat mild to moderate memory and mental impairment; Xuanning for hypertension; Duomeisu for lymphoma, multiple myeloma, ovarian and breast cancers, and other malignant tumors; Jinyouli to prevent leucopenia and infection induced by chemotherapy; Enxi to treat adult idiopathic Parkinson's disease; Keaili for breast cancer; Shuluoke, Nuomoling, Weihong, and Xinweihong for various infections; and Encun to prevent atherosclerotic thrombosis events. It also offers Qixiao to treat upper respiratory tract infection; Linmeixin and Shuanglexin for diabetes; Gubang and Gubangjia to treat osteoporosis in postmenopausal women; Gaoshunsong for arthritis, rheumatoid, and various pain; Debixin for various ulcer; and Qimaite for acute and chronic pains. In addition, the company provides antibiotics, vitamin C, and caffeine APIs; functional food and glucose products; and researches and develops various products with focus on the therapeutic areas of oncology, autoimmunity, psychiatry and neurology, digestion and metabolism, cardio-cerebrovascular system, and anti-infection. Further, it offers healthcare services and sells pharmaceutical equipment. The company was formerly known as China Pharmaceutical Group Limited and changed its name to CSPC Pharmaceutical Group Limited in March 2013. CSPC Pharmaceutical Group Limited was incorporated in 1992 and is headquartered in Shijiazhuang, the People's Republic of China.